HC Wainwright Forecasts Stronger Earnings for Traws Pharma

Traws Pharma, Inc. (NASDAQ:TRAW – Free Report) – Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Traws Pharma in a research note issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($1.00) per share for the year, up from their prior forecast of ($1.17). HC Wainwright has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for Traws Pharma’s Q4 2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at $0.09 EPS.

Traws Pharma (NASDAQ:TRAW – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.00.

View Our Latest Analysis on Traws Pharma

Traws Pharma Stock Up 3.9%

Shares of TRAW opened at $0.24 on Thursday. The company has a 50 day moving average price of $0.41 and a 200-day moving average price of $1.04. Traws Pharma has a fifty-two week low of $0.22 and a fifty-two week high of $3.23.

About Traws Pharma

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Read More

Earnings History and Estimates for Traws Pharma (NASDAQ:TRAW)

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.